Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
Open accessThe DOI matches its Crossref record; 621 of the 628 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked insulin resistance, independent of obesity. This article summarizes the state of the science since we last reviewed the field in the Endocrine Reviews in 1997. There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity. There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary. Constitutive activation of serine kinases in the MAPK-ERK pathway may contribute to resistance to insulin's metabolic actions in skeletal muscle. Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis. Genetic disruption of insulin signaling in the brain has indicated that this pathway is important for ovulation and body weight regulation. These insights have been directly translated into a novel therapy for PCOS with insulin-sensitizing drugs. Furthermore, androgens contribute to insulin resistance in PCOS. PCOS may also have developmental origins due to androgen exposure at critical periods or to intrauterine growth restriction. PCOS is a complex genetic disease, and first-degree relatives have reproductive and metabolic phenotypes. Several PCOS genetic susceptibility loci have been mapped and replicated. Some of the same susceptibility genes contribute to disease risk in Chinese and European PCOS populations, suggesting that PCOS is an ancient trait.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance and hyperinsulinemia, either directly or indirectly, through factors such as adiposity can lead to increase circulating androgen levels (6).”
From Obstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis (2025) · cites this paper as [6]
In the citing paper
“Androgen excess favors visceral fat deposition and lipid dysfunction with a vicious cycle of worsening of hyperinsulinemia and insulin resistance (6).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [6]
In the citing paper
“primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [163]
In the citing paper
“Moreover, women who have both obesity and PCOS exhibit a greater level of insulin resistance in comparison to obese persons who do not have PCOS [53].”
In the citing paper
“Consensus is yet to be achieved in lean women with PCOS as IR is not consistently demonstrated (Diamanti-Kandarakis and Dunaif, 2012).”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Diamanti-Kandarakis and Dunaif, 2012
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Research works printed but not linked: 5
- Achard, 1921, Le virilisme et son association à l'insuffisance glycolytique (diabète des femmes à barbe), Bull Acad Natl Med (Paris), 86, 51
- Vague, 1947, La différentiation sexuelle. Facteur determinant des formes de l'obesité, Presse Med, 55, 339
- Chereau, 1844, Mémoires pour servir à l'étude des malades ovaires
- Givens, 1992, Historical Overview of the Polycystic Ovary, 3
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 377
Cited by
Items 501–600 of 1,006
Greenwood, E. A., Pasch, L. A., Cedars, M. I., & Huddleston, H. G. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.01.016 · Cited by 41
Mizgier, M., Jarząbek‐Bielecka, G., Opydo-Szymaczek, J., Wendland, N., Więckowska, B., & Kędzia, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9093041 · Cited by 41
Rodent models of polycystic ovary syndrome
McNeilly, A. S., & Duncan, W. C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.007 · Cited by 41
Zhang, X., Huang, L., Su, H., Chen, Y., Huang, J., He, C., Li, P., Yang, D., & Wan, J. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.02.014 · Cited by 41
PCOS in Adolescence and Type 2 Diabetes
Carreau, A.-M., & Baillargeon, J.-P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0564-3 · Cited by 40
Lu, C., Cardoso, R. C., Puttabyatappa, M., & Padmanabhan, V. (2016) · Biology of Reproduction · doi:10.1095/biolreprod.115.136283 · Cited by 40
“At the adipose tissue level, the finding of normal responsiveness to insulin in prenatal T-treated females is also consistent with observations in PCOS women of no differences in the abundance of several insulin-signaling molecules at basal levels [63] and after insulin stimulation of isolated adipocytes [7, 64].”
BackgroundResultWaghmare, S. V., & Shanoo, A. (2023) · Cureus · doi:10.7759/cureus.47408 · Cited by 40
“Females with PCOS are at an increased risk of developing type 2 diabetes and impaired glucose tolerance [17].”
Aliyu, U., Toor, S. M., Abdalhakam, I., Elrayess, M. A., Samra, A. B. A., & Albagha, O. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1591677 · Cited by 43
Developmental Programming of PCOS Traits: Insights from the Sheep
Cardoso, R. C., & Padmanabhan, V. (2019) · Medical Sciences · doi:10.3390/medsci7070079 · Cited by 40
“In addition, approximately 70% of PCOS patients exhibit metabolic disturbances, such as obesity and insulin resistance [4].”
BackgroundZhao, J., Huang, J., Geng, X., Chu, W., Li, S., Chen, Z., & Du, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00772 · Cited by 40
Cai, H., Mol, B. W., Gordts, S., Wang, H., Wang, T., Li, N., & Shi, J. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16590 · Cited by 40
Krentowska, A., Łebkowska, A., Jacewicz‐Święcka, M., Hryniewicka, J., Leśniewska, M., Adamska, A., & Kowalska, I. (2021) · Endocrine · doi:10.1007/s12020-020-02596-8 · Cited by 40
Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women
Li, W., Hu, H., Zou, G., Ma, Z., Liu, J., & Li, F. (2021) · Medicine · doi:10.1097/md.0000000000026049 · Cited by 40
Falcetta, P., Benelli, E., Molinaro, A., Cosmo, C. D., Bagattini, B., Ghianda, S. D., Salvetti, G., Fiore, E., Pucci, E., Fruzzetti, F., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01594-5 · Cited by 40
Mitrašinović‐Brulić, M., Buljan, M., & Suljević, D. (2021) · Middle East Fertility Society Journal · doi:10.1186/s43043-021-00085-0 · Cited by 41
“It is estimated that about 50–80% of patients with PCOS develop insulin resistance, which correlates with insulin production [32].”
BackgroundPersistent Apparent Pancreatic β-Cell Defects in Premenarchal PCOS Relatives
Torchen, L. C., Fogel, N. R., Brickman, W. J., Paparodis, R., & Dunaif, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1474 · Cited by 33
Self-citationSerum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome
Adamska, A., Karczewska‐Kupczewska, M., Łebkowska, A., Milewski, R. J., Górska, M., Otziomek, E., Nikołajuk, A., Wołczyński, S., & Kowalska, I. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0249 · Cited by 41
Song, D. K., Hong, Y. S., Sung, Y., & Lee, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178120 · Cited by 40
Targher, G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1610000 · Cited by 40
Rashid, R., Tripathi, R., Singh, A., Sarkar, S., Kawale, A. K., Bader, G. N., Gupta, S., Gupta, R., & Jha, R. K. (2023) · Phytotherapy Research · doi:10.1002/ptr.7860 · Cited by 39
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
Chauvin, S. (2025) · Biomolecules · doi:10.3390/biom15070923 · Cited by 40
“Molecular analyses have revealed that this resistance is associated, depending on the PCOS cohort, with the down-regulation of the insulin receptor β -subunit in lean women with PCOS, along with defects in post-receptor signaling [85,92,107].”
Wang, Y., Fu, X., Xu, J., Wang, Q., & Kuang, H. (2016) · Scientific Reports · doi:10.1038/srep28089 · Cited by 35
Several critical genes and microRNAs associated with the development of polycystic ovary syndrome
Wang, W., Ji, J., Li, J., Ren, Q., Gu, J., Zhao, Y., Hong, D., Guo, Q., & Tan, Y. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2019.10.002 · Cited by 39
Solorzano, C. M. B., & McCartney, C. R. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.003 · Cited by 39
“The resulting compensatory hyperinsulinemia augments ovarian and adrenal androgen production, reduces hepatic SHBG production (increasing androgen bioavailability), and disrupts ovarian follicular dynamics and function [8].”
BackgroundXie, Y., Xiao, L. Y., & Li, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701590 · Cited by 39
Li, X., Liu, X., Zuo, Y., Gao, J., Liu, Y., & Zheng, W. (2021) · Medicine · doi:10.1097/md.0000000000026521 · Cited by 39
“Therefore, when the amount of insulin secretion is not enough to meet the needs of IR, that is, when insulin secretion is decompensated, fasting and abnormal glucose tolerance occur during pregnancy in PCOS patients, leading to the occurrence of gestational diabetes.([47,48]) The results of this study show that the de…”
ResultYang, Y., Zhou, C.-C., Hu, H., Fukuzawa, I., & Zhang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1035929 · Cited by 39
“There is general agreement that PCOS patients are insulin resistant, especially obese PCOS patients (107).”
BackgroundBalkrishna, A., Rana, M., Mishra, S., Srivastava, D., Bhardwaj, R., Singh, S., Rajput, S. K., & Arya, V. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/3705508 · Cited by 39
“In turn, more muscle mass aids in the fght against insulin resistance, which is one of the cornerstones of PCOS control [46].”
BackgroundThe association between hyperandrogenemia and the metabolic syndrome in morbidly obese women
Valderhaug, T. G., Hertel, J. K., Nordstrand, N., Dale, P. O., Hofsø, D., & Hjelmesæth, J. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0040-5 · Cited by 35
“Background The polycystic ovarian syndrome (PCOS) is the most common female endocrinopathy, affecting 8 – 12 % of women of reproductive age [1], and 10–35 % of obese women [2–4].”
BackgroundMetformin in women with PCOS, Pros
Pasquali, R. (2014) · Endocrine · doi:10.1007/s12020-014-0311-1 · Cited by 39
Impact of hypocaloric dietary intervention on ovulation in obese women with PCOS
Jarrett, B. Y., & Lujan, M. E. (2017) · Reproduction · doi:10.1530/rep-16-0385 · Cited by 39
“PCOS exists on a spectrum, and the diagnosis encompasses a broad range of severity of reproductive and metabolic abnormalities (Diamanti-Kandarakis & Dunaif 2012, Fauser et al.”
Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome
Boumosleh, J. M., Grundy, S. M., Phan, J., Neeland, I. J., Chang, A. Y., & Vega, G. L. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00323 · Cited by 39
“In contrast, our obese womenwith PCOS features had higherHOMA-IR than that of corresponding non-PCOSwomen; this is consistent with previous reports [31, 32].”
BackgroundResultLocal Cortisol Elevation Contributes to Endometrial Insulin Resistance in Polycystic Ovary Syndrome
Qi, J., Wang, W., Zhu, Q., He, Y., Lu, Y., Wang, Y., Li, X., Chen, Z., & Sun, Y. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02459 · Cited by 39
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38
“PCOS is defined by its reproductive features of hyperandrogenism, chronic oligoanovulation, and/or polycystic ovarian morphology [2].”
BackgroundJamilian, M., & Asemi, Z. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000438465 · Cited by 38
Parker, J., Briden, L., & Gersh, F. L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124021 · Cited by 41
Gui, J., & Wang, R. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.03.018 · Cited by 38
Paganini, C., Peterson, G., Stavropoulos, V., & Krug, I. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666171204151209 · Cited by 35
“Therefore, androgen excess might contribute to insulin resistance in women with PCOS, potentially setting up a vicious cycle whereby hyperinsulinemia might promote the production of androgens, which in turn contributes to insulin resistance [69].”
BackgroundOrtiz-Flores, A. E., Luque‐Ramírez, M., Fernández‐Durán, E., Álvarez‐Blasco, F., & Escobar-Morreale, H. F. (2019) · Metabolism · doi:10.1016/j.metabol.2019.01.015 · Cited by 38
Precise Personalized Medicine in Gynecology Cancer and Infertility
Zhang, P.-Y., & Yu, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00382 · Cited by 38
Clinicians’ perspectives on diagnosing polycystic ovary syndrome in Australia: a qualitative study
Copp, T., Muscat, D. M., Hersch, J., McCaffery, K. J., Doust, J., Mol, B. W., Dokras, A., & Jansen, J. (2020) · Human Reproduction · doi:10.1093/humrep/deaa005 · Cited by 37
circPUM1 promotes polycystic ovary syndrome progression by sponging to miR-760
Deng, L., Chen, Q., Xie, J., Wei, W., & Hui, H. (2020) · Gene · doi:10.1016/j.gene.2020.144903 · Cited by 38
MiRNAs expression profiling of rat ovaries displaying PCOS with insulin resistance
Zhang, C., Yu, C., Lin, Z., Pan, H., Li, K., & Ma, H. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05730-z · Cited by 38
Tarkesh, F., Jahromi, B. N., Hejazi, N., & Tabatabaee, H. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.1837 · Cited by 38
“Although the underlying etiology of PCOS is not clearly understood, insulin resistance has been suggested as the major cause (Diamanti-Kandarakis & Dunaif, 2012).”
BackgroundOxidative stress and female reproductive disorder: A review
Manokaran, K., Bhat, P., Deepak Nayak, M., Bhaskaran, R. S., Paramasivam, P., Ahmed, S. F., Priya, K., Pai, K. S. R., & Balaji, V. E. (2022) · Asian Pacific Journal of Reproduction · doi:10.4103/2305-0500.346088 · Cited by 39
Zhang, Z., Shi, C., & Wang, Z. (2023) · Nutrients · doi:10.3390/nu15132833 · Cited by 38
Rahmatnezhad, L., Moghaddam‐Banaem, L., Behroozi-Lak, T., Shiva, A., & Rasouli, J. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01160-z · Cited by 39
“Approximately, 80–90% of women experiencing irregular menstrual periods display elevated levels of circulating androgens [18].”
BackgroundOptimal management of subfertility in polycystic ovary syndrome
Bates, G. W., & Berger, J. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s48527 · Cited by 38
“This number changes little when comparing different races or ethnicities, although the phenotypic expressions do differ slightly.(5) The syndrome gets its name from the polycystic appearance of the ovaries that result from arrested follicular development and ovulatory dysfunction.”
The impact of body mass on inflammatory markers and insulin resistance in polycystic ovary syndrome
Souza dos Santos, A. C., Soares, N. P., Costa, E. C., de Sá, J. C. F., Azevedo, G. D., & Lemos, T. M. A. M. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.976546 · Cited by 36
“The inflammatory state is mainly evidenced by elevated plasma concentrations of inflammatory cytokines: tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6) [8] and the acute phase C-reactive protein (CRP), common in patients with PCOS, which contribute to IR and other cardiometabolic risk factors in the long…”
BackgroundKogure, G. S., Silva, R. C., Furtado, C. L. M., Ribeiro, V. B., Pedroso, D. C. C., de Melo, A. S., Ferriani, R. A., & dos Reis, R. M. (2018) · The Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000002714 · Cited by 38
“The excess androgen favors the deposition of abdominal fat in these women, which may exacerbate the adverse metabolic effects of PCOS (11).”
BackgroundChen, T., Yu, Y., Jia, F., Luan, P., & Liu, X. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.960965 · Cited by 37
Gao, Y., Liu, H., Qiao, L., Liang, J., Yao, H., Lin, X., & Gao, Y. (2023) · Healthcare · doi:10.3390/healthcare11040562 · Cited by 38
Macut, D., Bačević, M., Božić-Antić, I., Bjekić-Macut, J., Čivčić, M., Erceg, S., Vojnović Milutinović, D., Stanojlović, O., Andrić, Z., Kastratović-Kotlica, B., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/812610 · Cited by 33
“It is assumed that 60–80% of PCOS women have hyperandrogenemia [29] and that the cardiometabolic risk is prevalent in hyperandrogenic PCOS phenotypes [30].”
BackgroundEvolutionary determinants of polycystic ovary syndrome: part 1
Ünlütürk, U., Sezgın, E., & Yıldız, B. O. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.010 · Cited by 37
“The phenotype of PCOS at greatest risk for insulin resistance and its related metabolic features are those defined by the National Institutes of Health (NIH) 1990 criteria (49, 50).”
BackgroundDevelopmental Programming of Ovarian Functions and Dysfunctions
Puttabyatappa, M., & Padmanabhan, V. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.01.017 · Cited by 37
“Majority of patients with PCOS are at increased risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular diseases (Diamanti-Kandarakis and Dunaif 2012, Moran, et al. 2015).”
BackgroundAn Update on the Progress of Endometrial Receptivity in Women with Polycystic Ovary Syndrome
Zhao, J., Chen, Q., & Xue, X. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00641-z · Cited by 37
Yang, Y., Lang, P., Zhang, X., Wu, X., Cao, S., Zhao, C. L., Shen, R., Ling, X., Yang, Y., & Zhang, J. (2023) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-023-02724-z · Cited by 37
“Insulin receptor substrate-related serine phosphorylation affects the metabolism of classical insulin target tissues, which may be the mechanism of PCOS defect after the characteristic combination of insulin action [59, 60].”
BackgroundŞahin, F. K., Şahin, S. B., Ural, Ü. M., Cüre, M. C., Şentürk, Ş., Tekın, Y. B., Balık, G., Cüre, E., Yuce, S., & Kırbaş, A. (2015) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2015.432 · Cited by 37
“lar diseases [4].”
Wanderley, M. D. S., Pereira, L. C. R., Santos, C. B., da Cunha, V. S., & Neves, M. V. J. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1642634 · Cited by 37
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
“Insulin has a gonadotropin-like action and may increase androgen production, which contributes to worsening both metabolic impairment and clinical picture [8].”
BackgroundKazemi, M., Pierson, R. A., McBreairty, L. E., Chilibeck, P. D., Zello, G. A., & Chizen, D. R. (2020) · Clinical Endocrinology · doi:10.1111/cen.14179 · Cited by 36
Heidarzadehpilehrood, R., Pirhoushiaran, M., Osman, M. B., Hamid, H. A., & Ling, K. (2023) · Biomedicines · doi:10.3390/biomedicines11020518 · Cited by 36
Ainehchi, N., Khaki, A., Farshbaf‐Khalili, A., Hammadeh, M. E., & Ouladsahebmadarek, E. (2019) · Biomolecules · doi:10.3390/biom9060215 · Cited by 36
Ahmed, N., Batarfi, A. A., Bajouh, O. S., & Bakhashab, S. (2019) · Diagnostics · doi:10.3390/diagnostics9040136 · Cited by 36
Morgante, G., Troìa, L., & Leo, V. D. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105770 · Cited by 36
Bai, L., Wang, W., Yu, X., Wang, S., Wan, S., & Zhu, Y. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.11.005 · Cited by 36
“In granulosa cells, TP53 is mainly working as a mediator responding to the various harmful stimulations to control the initiation of cell apoptosis.48,49 Meanwhile, TP53 has been reported to participate in the regulation of cell proliferation and steroidogenesis in granulosa cells.50,51 In our present study, we found…”
BackgroundInfluentialThe role of alpha lipoic acid in female and male infertility: a systematic review
Tucci, C. D., Galati, G., Mattei, G., Bonanni, V., Capri, O., D'Amelio, R., Muzii, L., & Panici, P. B. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1843619 · Cited by 36
“resistance (IR) and more than 50% of them are obese [25,26].”
BackgroundAGEs-related dysfunctions in PCOS: evidence from animal and clinical research
Tatone, C., Emidio, G. D., Placidi, M., Rossi, G., Ruggieri, S., Taccaliti, C., D’Alfonso, A., Amicarelli, F., & Guido, M. (2021) · Journal of Endocrinology · doi:10.1530/joe-21-0143 · Cited by 37
Yu, T., Wu, D., Cao, Y., & Zhai, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.740377 · Cited by 36
Jung, W., Choi, H., Kim, J., Kim, J., Kim, W., Nurkolis, F., & Kim, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20889 · Cited by 36
Polycystic Ovary Syndrome in Adolescents
Witchel, S. F., Roumimper, H., & Oberfield, S. E. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.01.004 · Cited by 36
Bishop, C. V., Stouffer, R. L., Takahashi, D. L., Mishler, E., Wilcox, M. C., Slayden, O. D., & True, C. A. (2018) · Human Reproduction · doi:10.1093/humrep/dey013 · Cited by 36
Calcaterra, V., Magenes, V. C., Massini, G., De Sanctis, L., Fabiano, V., & Zuccotti, G. (2024) · Nutrients · doi:10.3390/nu16070938 · Cited by 35
“Indeed, the major players in the pathogenesis of PCOS appear to be abnormal ovarian steroidogenesis and folliculogenesis [38,39], IR and hyperinsulinemia [38,40,41], and reproductive neuroendocrine dysfunction [41,42].”
BackgroundCurrent and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
“PCOS associated IR selectively affects metabolic but not mitogenic or steroidogenic insulin actions [26,27].”
BackgroundPOLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Genetics of polycystic ovary syndrome (PCOS)
Louwers, Y. V., Visser, J. A., Dunaif, A. E., & Laven, J. S. E. (2025) · Reproduction · doi:10.1530/rep-25-0126 · Cited by 35
“PCOS is commonly associated with insulin resistance and obesity, disorders that confer increased risk for type 2 diabetes (T2D) (Rubin et al. 2017) as well as for other serious cardiometabolic morbidities across the lifespan (Diamanti-Kandarakis & Dunaif 2012).”
Self-citationAmato, M. C., Magistro, A., Gambino, G., Vesco, R., & Giordano, C. S. D. S. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0600 · Cited by 35
Puttabyatappa, M., Lü, C., Martin, J. D., Chazenbalk, G. D., Dumesic, D. A., & Padmanabhan, V. (2018) · Reproductive Sciences · doi:10.1177/1933719117746767 · Cited by 35
“Metabolic diseases such as obesity, type 2 diabetes mellitus, and polycystic ovary syndrome (PCOS) are usually associated with systemic insulin resistance (IR) and adipose tissue dysfunction.(1,2) The relationship between adipose tissue dysfunction and IR is so strong that either buildup of adipose tissue as in obesit…”
BackgroundAbuelEzz, N. Z., Shabana, M. E.-A., Rashed, L. A., & Morcos, G. N. B. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s323962 · Cited by 35
“HOMA-IR of more than 2 was considered as insulin resistance.(35)”
BackgroundSerum asprosin level in different subtypes of polycystic ovary syndrome: a cross-sectional study
Jiang, Y., Liu, Y., Yu, Z., Yang, P., xie, L., Shang, X., & Zhao, S. (2021) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20201147 · Cited by 35
Yang, X., Wang, K., Lang, J., Guo, D., Gao, H., Qiu, Y., Jin, X., Zhang, M., Shi, J., Ma, Q., et al. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01994-6 · Cited by 35
“Ovary insulin resistance (IR) is considered as a key clinical characteristic of PCOS [2], especially in obese PCOS.”
BackgroundThe role of B cells in immune cell activation in polycystic ovary syndrome
Ascani, A., Torstensson, S., Risal, S., Lu, H., Eriksson, G., Li, C., Teschl, S., Menezes, J., Sándor, K., Ohlsson, C., et al. (2023) · eLife · doi:10.7554/elife.86454 · Cited by 35
Stener‐Victorin, E., Maliqueo, M. A., Soligo, M., Protto, V., Manni, L., Jerlhag, E., Kokosar, M., Sazonova, A. P., Behre, C. J., Lind, M., et al. (2016) · Obesity Science & Practice · doi:10.1002/osp4.78 · Cited by 35
“Independent of body weight, insulin sensitivity is ~40% lower in women with PCOS than in controls, and insulin resistance has been attributed to defects in insulin signaling in adipocytes and skeletal muscle (2).”
BackgroundElevated levels of arachidonic acid metabolites in follicular fluid of PCOS patients
Li, S., Qi, J., Tao, Y., Zhu, Q., Huang, R., Liao, Y., Yue, J., Liu, W., Zhao, H., Yin, H., et al. (2020) · Reproduction · doi:10.1530/rep-19-0136 · Cited by 35
Xu, W., Tang, M., Wang, J., & Wang, L. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/4086864 · Cited by 35
“Studies have shown that the MAPK signalling pathway plays an important role in the proliferation of ovarian granulosa cells [35, 36].”
BackgroundCastillo-Higuera, T., Alarcón-Granados, M. C., Marín-Suarez, J., Moreno-Ortíz, H., Esteban-Pérez, C. I., Ferrebuz, A., Forero‐Castro, M., & Villalba, G. E. C. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00375-4 · Cited by 35
Papakonstantinou, E., Kechribari, I., Mitrou, P., Trakakis, E., Vassiliadi, D., Georgousopoulou, E., Zampelas, A., Kontogianni, M. D., & Dimitriadis, G. (2016) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2015.225 · Cited by 34
Varlamov, O., Bishop, C. V., Handu, M., Takahashi, D., Srinivasan, S., White, A., & Roberts, C. T. (2017) · Human Reproduction · doi:10.1093/humrep/dex244 · Cited by 34
“…is a common disorder of reproductive age associated with ovarian dysfunction and infertility, which results in metabolic disturbances (Solomon, 1999) such as obesity and insulin resistance (IR) (Wagenknecht et al., 2003; Escobar-Morreale and San Millan, 2007; Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundHuang, X., Wang, Q., Liu, T., Pei, T., Liu, D., Zhu, H., & Huang, W. (2019) · Endocrine · doi:10.1007/s12020-019-01912-1 · Cited by 34
Saadati, N., Haidari, F., Barati, M., Nikbakht, R., Mirmomeni, G., & Rahim, F. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08338 · Cited by 34
“Because insulin plays an important role in PCOS and its metabolic features, controlling the disease with diet is the best step for people who want to manage PCOS and its associated symptoms [46, 47].”
Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population
Mansour, A., Mirahmad, M., Mohajeri‐Tehrani, M. R., Jamalizadeh, M., Hosseinimousa, S., Rashidi, F., Asili, P., & Sajjadi‐Jazi, S. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-37513-2 · Cited by 34
Cao, Z., Zhou, Q., An, J., Guo, X., Jia, X., & Qiu, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s525651 · Cited by 34
“15,16 Despite decades of research, the precise etiology of PCOS remains unclear.”
Mice endometrium receptivity in early pregnancy is impaired by maternal hyperinsulinemia
Li, R., Wu, J., He, J., Wang, Y., Liu, X., Chen, X., Tong, C., Ding, Y., Su, Y., Chen, W., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6322 · Cited by 34
“Hyperinsulinemia and insulin resistance are established characteristics of women with PCOS, obesity and type 2 diabetes (32,33).”
Lai, W., Li, X., Zhu, H., Zhu, X., Tan, H., Feng, P., Chen, L., & Luo, C. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104535 · Cited by 34
Douma, Z., Dallel, M., Bahia, W., Salem, A. B., Hachani, F., Almawi, W. Y., Lautier, C., Haydar, S., Grigorescu, F., & Mahjoub, T. (2020) · Gene · doi:10.1016/j.gene.2020.144560 · Cited by 34
Dietary Control of Inflammation and Resolution
Sears, B., & Saha, A. K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.709435 · Cited by 35
“Furthermore, other chronic conditions related to increased insulin resistance include hypertension (141), cardiovascular disease (142), polycystic ovary syndrome (143), chronic kidney disease (144), various types of cancer (145), depression (146), and neurodegenerative diseases such as Alzheimer’s and Parkinson’s (147…”
BackgroundChen, W., Huang, Q.-Y., Wang, Z., Zhuang, X., Lin, S., & Shi, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.918805 · Cited by 36
Pathological Role of Reactive Oxygen Species on Female Reproduction
Goutami, L., Jena, S. R., Swain, A., & Samanta, L. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-12966-7_12 · Cited by 34
Pukajło, K., Łaczmański, Ł., Kolačkov, K., Kuliczkowska-Płaksej, J., Bolanowski, M., Milewicz, A., & Daroszewski, J. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1065482 · Cited by 34
“However, in the PCOS pathogenesis the pivotal role of hyperinsulinemia and insulin resistance (IR) is highlighted [2,5,6].”
BackgroundIndustrial endocrine disruptors and polycystic ovary syndrome
Palioura, E., & Diamanti‐Kandarakis, E. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346762 · Cited by 34
Self-citation
Metadata
- Authors
- Diamanti-Kandarakis, E., & Dunaif, A.
- Affiliations
- Medical School, University of Athens (E.D.-K.), Athens GR-14578, Greece
- Northwestern University (US)
- ORCID
- Dunaif, Andrea
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-10-12
- Volume
- 33
- Issue
- 6
- Pages
- 981-1030
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC5393155
- OpenAlex
- W1967263394
- Semantic Scholar
- b2b7fa060bf61f261edf17bef51cbbbd222742e0
- Cited by
- 1,947
- References
- 628
- Citations by year
- 2026: 183 · 2025: 178 · 2024: 182 · 2023: 221 · 2022: 191 · 2021: 184 · 2020: 136 · 2019: 140 · 2018: 108 · 2017: 97 · 2016: 96 · 2015: 92 · 2014: 91 · 2013: 43 · 2012: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073411)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD044405, R01HD057223, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, insulin resistance, insulin receptor signaling, MAPK/ERK pathway, skeletal muscle insulin sensitivity, ovarian steroidogenesis, ovulation, brain insulin signaling, body weight regulation, insulin-sensitizing drugs, androgens, developmental origins of health and disease, fetal growth restriction, genetic susceptibility loci, type 2 diabetes risk, lean PCOS
- MeSH terms
- Female, Humans, Insulin Resistance, Phenotype, Polycystic Ovary Syndrome, Reproduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.